FIA
IGC icon

FNY Investment Advisers’s IGC Pharma IGC Stock Holding History

FNY Investment Advisers’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,000
Closed -$11.7K – 816
2021
Q4 		$11K Buy
+12,000
New +$16.1K 0.01% 380

Other funds holding IGC

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
DP
Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

FNY Investment Advisers's IGC Position: Q1 2022 in Review

FNY Investment Advisers sold out of IGC Pharma (IGC) in Q1 2022, closing a stake of 12,000 shares — an estimated $11.7K sold.

FNY Investment Advisers first reported a position in IGC in Q4 2021 and held it in 1 quarter. The position peaked at $11K in Q4 2021. 29 funds tracked by Wall St. Rank hold IGC as of Q1 2022.

  • FNY Investment Advisers reported no remaining IGC Pharma position as of Q1 2022 after selling out during the quarter.
  • FNY Investment Advisers sold 12,000 IGC Pharma shares in Q1 2022, an estimated $11.7K.
  • FNY Investment Advisers first reported a position in IGC Pharma in Q4 2021 and held it in 1 quarter.
  • FNY Investment Advisers's IGC Pharma position peaked at $11K in Q4 2021.
  • 29 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2022.

Based on FNY Investment Advisers's 13F filing for Q1 2022, filed 25 Apr 2022.